March 10, 2020 – Filipino patients suffering from coronary artery disease or peripheral artery disease (CAD/PAD) may no longer need to look further to reduce their risk of major adverse cardiovascular events as a lower dosage of rivaroxaban has been introduced in the country for the new indication along with aspirin. This development is a major highlight presented by the Team Xarelto of Bayer Pharmaceuticals during the first successful Anti-coagulation Experts’ Summit at the Peninsula Manila. The summit was culminated by Dr. Christopher Hammett’s presentation of the COMPASS study showing that combined treatment of rivaroxaban (approved by the Food and Drug Administration) 2.5 mg twice daily and acetylsalicylic acid (aspirin) 100 mg once daily resulted in a significant reduction in major cardiovascular events, including myocardial infarction, stroke, and cardiovascular death. It demonstrated lower risk of occurrence of such incidents compared to taking rivaroxaban alone or acetylsalicylic acid by itself. It is notable that the COMPASS study was stopped 1 year ahead of expectations in February 2017 due to overwhelming efficacy from the said combined treatment.